• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AIXC

    AIxCrypto Holdings Inc.

    Subscribe to $AIXC
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2015

    Exchange: NASDAQ

    Recent Analyst Ratings for AIxCrypto Holdings Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    AIxCrypto Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. SEC Filings

    View All

    SEC Form 10-K filed by AIxCrypto Holdings Inc.

    10-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/30/26 6:21:26 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/27/26 4:30:35 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/27/26 4:05:53 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/17/26 4:05:38 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/2/26 5:03:24 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AIxCrypto Holdings Inc.

    SCHEDULE 13G/A - AIxCrypto Holdings, Inc. (0001460702) (Subject)

    1/29/26 4:05:27 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    1/6/26 1:32:44 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/15/25 8:03:33 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by AIxCrypto Holdings Inc.

    DEF 14A - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/15/25 10:11:02 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by AIxCrypto Holdings Inc.

    EFFECT - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/12/25 12:15:14 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing Progress

    LOS ANGELES, April 6, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) and on-chain asset ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting continued progress in the Company's AI Agent strategy, including ongoing development across key modules and the start of initial internal enterprise testing aimed at supporting workflow optimization and practical use case refinement. Advancing AI Agent-Related Development EffortsThis week, AIxC continued to advance its broader AI Agent strategy, with development work across key modules and supporting i

    4/6/26 11:42:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Highlights Full Year 2025 Transformation and Next Phase of Growth

    LOS ANGELES, March 30, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI ("EAI") ecosystem, today highlighted key takeaways from its recently released full year 2025 results and provided an update on the Company's continued strategic development. Annual Report HighlightsFiscal year 2025 marked a foundational year for AIxC's strategic transformation. As outlined in the Company's annual results, AIxC completed its transition toward AI- and blockchain-enabled digital infrastructure, strengthened its capital position through financing activities, including the completion of a $41.0 million PIPE

    3/30/26 4:48:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIXCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Real Estate Industry Engagement, Long-Term Infrastructure Direction, and Industry Signals From the Evolving AI Stack

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting recent industry engagement, the Company's continued long-term infrastructure focus, and broader industry developments relevant to the evolving AI Agent economy. Strategic Industry EngagementThis week, Jerry Wang attended the annual meeting of Pinnacle Real Estate Group in California. The Company believes that engagement with established participants in real-world industries may help inform future infrastructure opportunities rela

    3/24/26 2:00:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Acknowledges Conclusion of SEC Investigation with no Enforcement Action Involving majority controlling stockholder, Faraday Future and Reaffirms Strategic Focus

    LOS ANGELES, March 22, 2026 /PRNewswire/ -- AIxCrypto Holdings Inc. (NASDAQ:AIXC) ("AIxCrypto" or the "Company") today acknowledged the public announcement made by its majority controlling stockholder, Faraday Future Intelligent Electric Inc., regarding the conclusion of a previously disclosed U.S. Securities and Exchange Commission (SEC) investigation, which FFAI announced has been resolved with no enforcement action recommended. The Company views this development as an important step toward reducing prior uncertainty associated with the matter. Investors and other interested parties should refer to FFAI's public filings and disclosures for additional information.Significance to AIxCryptoFr

    3/22/26 11:52:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Exploration of Infrastructure for the Emerging AI Agent Economy

    LOS ANGELES, March 16, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting the Company's ongoing exploration of strategic opportunities related to the emerging AI Agent economy and its continued focus on infrastructure that may support future ecosystem development across intelligent software agents, connected devices, and real-world application scenarios. Exploring Infrastructure for the Emerging AI Agent EconomyAs AI Agents continue to evolve from assistive software tools into systems capable of task e

    3/16/26 6:29:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agent Ecosystem Application Progress and Infrastructure Development

    LOS ANGELES, March 10, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting continued progress across core Agent ecosystem applications, including REE platform development, Agentir advancement, developer-facing architecture, and early device connectivity infrastructure. Advancing Core Agent Ecosystem ApplicationsThis week, AIxC continued to advance application-layer development across the EAI × Agent ecosystem, with priority placed on accelerating delivery of live product workflows. Core modules of the R

    3/10/26 6:31:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Scaling the Ecosystem, Hub S2 Momentum, and AI Agent Framework Development

    LOS ANGELES, March 3, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on Embodied AI (EAI) infrastructure, today shared a weekly business update from Co-CEO Jerry Wang. Strategic Refinement – Concentration on RWA and EAI InfrastructureDuring the week, Jerry Wang shared reflections on AIxC's evolving strategic direction.As part of an ongoing strategic refinement process, the Company is concentrating resources on its Real-World Asset (RWA) and Embodied AI (EAI) ecosystem initiatives. AIxC made the strategic decision to transition away from certain previously incubated initiatives, including the BesTrade AI Agent and Digital Asset AI Man

    3/3/26 5:46:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. Financials

    Live finance-specific insights

    View All

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials